Anti-inflammatory effects of rosuvastatin treatment on coronary artery ectasia patients of different age groups

Table 4 Comparison of serum hs-CRP and IL-6 levels in CAE patients treated with rosuvastatin

Groups	CAE-A (n = 60) (age ≤ 50)				CAE-B (n = 83) (50 < age ≤ 70)				CAE-C (n = 74) (age > 70)
	Pretreatment	Posttreatment	Delta	p-value	Pretreatment	Posttreatment	Delta	p-value	Pretreatment	Posttreatment	Delta	p-value
hs-CRP (mg/L)	32.3 ± 5.51	17.5 ± 2.38 ^*	15.1 ± 3.3	0.0001	26.1 ± 4.23	18.8 ± 2.74 ^*	9.4 ± 2.86	0.023	22.5 ± 4.82	19.8 ± 2.98	4.5 ± 3.12	0.310
IL-6 (pg/dL)	12.3 ± 1.5	6.4 ± 1.7^*	5.9 ± 1.6	0.021	10.9 ± 1.3	7.5 ± 2.0^*	3.0 ± 1.5	0.043	8.9 ± 1.1	7.6 ± 2.3	1.9 ± 1.5	0.519

CAE coronary artery ectasia, hs-CRP high-sensitivity C-reactive protein, IL-6 interleukin-6. Pretreatment: values measured at study inclusion. Posttreatment: values measured after 6 months of treatment with rosuvastatin. *: p < 0.05 vs corresponding pretreatment group

ISSN: 1471-2261